Skip to main content

Table 3 Univariate & multivariate analysis of risk factor for overall pulmonary toxicity

From: Effect of dose rate on pulmonary toxicity in patients with hematolymphoid malignancies undergoing total body irradiation

 

Univariate analysis

Multivariate analysis

SHR

95% CI

P-value

SHR

95% CI

P-value

Group

 Reduced dose rate group

1 (ref)

     

 Conventional dose rate group

1.86

0.93–3.71

0.078

2.61

1.26–5.40

0.010

Total dose (Gy)

1.19

0.94–1.51

0.156

1.38

1.04–1.83

0.025

Daily dose (Gy)

 Daily dose < 3

1 (ref)

     

 Daily dose ≥3

0.67

0.36–1.25

0.205

   

Women

1.23

0.70–2.18

0.471

Age at TBI (year)

1.00

0.98–1.02

0.723

Cancer type

 ALL

1 (ref)

     

 AML

1.47

0.81–2.67

0.210

 Others

1.17

0.56–2.44

0.682

Unrelated donor

1.22

0.70–2.10

0.482

Conditioning regimen

 Cyclophosphamide

1 (ref)

     

 Cy + othera

1.92

0.76–4.81

0.165

2.86

1.11–7.38

0.029

 Othersb

1.06

0.40 – 2.81

0.911

1.60

0.54–4.73

0.394

Prior chemotherapy regimens

 1

1 (ref)

     

 2

0.61

0.29–1.30

0.200

  ≥ 3

1.32

0.69–2.52

0.409

  1. P-by Fine-Gray
  2. SHR Sub-hazard ratios, ALL Acute lymphoblastic leukemia, AML Acute myeloid leukemia, GVHD Graft-versus-host disease
  3. a other: cytarabine, fludarabine, etoposide
  4. b others: cytarabine/fludaraibine, busulfan/fludarabine/etoposide, melphalan, melphalan/fludarabine, thiotepa